Navigation Links
Dendreon Announces Clinical Trial Plans for PROVENGE and DN24-02 at the American Society of Clinical Oncology Annual Meeting
Date:5/18/2011

>

PROVENGE Indication and Safety

PROVENGE is an autologous cellular immunotherapy for the treatment of asymptomatic or minimally symptomatic metastatic castrate resistant (hormone refractory) prostate cancer.

PROVENGE is intended solely for autologous use and is not routinely tested for transmissible infectious diseases.

The safety evaluation of PROVENGE was based on 601 prostate cancer patients in four randomized clinical trials who underwent at least one leukapheresis procedure. The most common adverse events (incidence greater than or equal to 15%) reported in patients in the PROVENGE group are chills, fatigue, fever, back pain, nausea, joint ache, and headache. Serious adverse events reported in patients in the PROVENGE group include acute infusion reactions (occurring within 1 day of infusion) and cerebrovascular events. In controlled clinical trials, severe (Grade 3) acute infusion reactions were reported in 3.5% of patients in the PROVENGE group. Reactions included chills, fever, fatigue, asthenia, dyspnea, hypoxia, bronchospasm, dizziness, headache, hypertension, muscle ache, nausea, and vomiting. No Grade 4 or 5 acute infusion reactions were reported in patients in the PROVENGE group.

To fulfill a post marketing requirement and as a part of the company's ongoing commitment to patients, Dendreon will conduct a registry of approximately 1,500 patients to further evaluate a small potential safety signal of cerebrovascular events. In four randomized clinical trials of PROVENGE in prostate cancer patients, cerebrovascular events were observed in 3.5% of patients in the PROVENGE group compared with 2.6% of patients in the control group.

For more information on PROVENGE, please see the full Prescribing Information at www.provenge.com or call Dendreon ON Call at 1-877-336-3736

About Dendreon

Dendreon Corporation is a biotechnology company w
'/>"/>

SOURCE Dendreon Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Dendreon Announces Presentation of PROVENGE Data at the 2011 American Society of Clinical Oncology Annual Meeting
2. Dendreon Announces Presentation of Data at the American Association of Cancer Research Annual Meeting
3. Dendreon Announces Webcast Presentations at Upcoming Conferences
4. Dendreon Expands Launch of PROVENGE
5. Dendreon Announces Exercise and Closing of Overallotment Option
6. Dendreon Announces Offering of $500 Million Convertible Senior Notes Due 2016
7. Dendreon Announces Webcast Presentation at J.P. Morgan Healthcare Conference
8. Dendreon Announces Presentation of PROVENGE Data at the American Society of Hematology and the Society of Urologic Oncology Annual Meetings
9. Dendreon Announces Webcast Presentation at Credit Suisse 2010 Health Care Conference
10. Dendreon Reports Third Quarter 2010 Financial Results
11. Dendreon Announces Presentation of PROVENGE Data at the 25th International Society for Biological Therapy of Cancer Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/27/2015)... Research and Markets ( http://www.researchandmarkets.com/research/t63pbj/medical_device ) has announced the ... Markets Seminar" conference to their offering. ... well established, the next growth area is ... with other countries in this region have all implemented, ... medical device regulations. This seminar will provide a comprehensive ...
(Date:7/27/2015)... and MENLO PARK, Calif. ... Pharmaceuticals, Inc. (OTCQX: DMPI) ("DelMar" and the ... commercializing proven cancer therapies in new orphan drug ... from institutional and accredited investors for a registered ... common stock and 3.35 million common stock purchase ...
(Date:7/27/2015)... , July 27, 2015  Cardica, Inc. (Nasdaq: CRDC ... its fiscal fourth quarter ended June 30, 2015, on Thursday, ... host a conference call at 4:30 p.m. Eastern Time to ... company,s business. Conference Call Details To access ... p.m. Eastern Time via phone, please dial 877-703-6106 from ...
Breaking Medicine Technology:Medical Device Regulation in Asia/Pacific Markets Seminar: London, UK - 21st, 22nd of September 2015 2DelMar Pharmaceuticals Announces Financing Update and Initial Subscriptions of $2.0 million in Registered Direct Offering 2DelMar Pharmaceuticals Announces Financing Update and Initial Subscriptions of $2.0 million in Registered Direct Offering 3Cardica To Announce Fiscal 2015 Fourth Quarter Financial Results On Thursday, August 6, 2015 2
... Candidate to Enter Clinical ... Studies in ... today it has initiated a Phase I clinical study of a ... safety, tolerability, and systemic pharmacokinetics of a topical,patch formulation of diclofenac ...
... Antisense Drug Targeting Glucagon Receptor for Treatment ... of Type 2 ... ) announced today it has earned $5,million from Ortho-McNeil, Inc. (OMI), a ... Phase 1,clinical trial of ISIS 325568. The collaboration between Isis and ...
Cached Medicine Technology:Cerimon Pharmaceuticals Initiates Phase I Clinical Study of Topical Diclofenac Sodium Patch 2Cerimon Pharmaceuticals Initiates Phase I Clinical Study of Topical Diclofenac Sodium Patch 3Isis Earns $5 Million Milestone Payment From Ortho-McNeil, Inc. for Initiation of Phase 1 Study of ISIS 325568 2Isis Earns $5 Million Milestone Payment From Ortho-McNeil, Inc. for Initiation of Phase 1 Study of ISIS 325568 3
(Date:7/27/2015)... ... 27, 2015 , ... On July 14, 2015, Harper’s Bazaar Magazine in an ... skin issues such as stretch marks , fine lines , and ... treatment options listed include lasers, ultrasound, radio frequency, Botox, and dermal fillers. It is ...
(Date:7/27/2015)... , ... July 27, 2015 , ... Eugene Batelli, D.P.M., ... accomplished athlete. “The patient is high-end athlete, whose accomplishments include running in 27 ... of Achilles tendon pain, which was diagnosed as tendinitis. I did an ultrasound ...
(Date:7/27/2015)... ... July 27, 2015 , ... The Maricopa Community Colleges today ... foster care system to get into and complete college. , The “Bridging Success ... an event today with partners from across the valley. , The initiative advisory board ...
(Date:7/27/2015)... New York, NY (PRWEB) , ... July 27, 2015 , ... ... North American tour. He will be performing for one additional night at each ... can add promo/coupon code DAVID-GILMOUR-2016 for added savings. , David Gilmour’s 2016 North America ...
(Date:7/27/2015)... , ... July 27, 2015 ... ... Global Calcium Propionate industry is a professional and in-depth research report. The ... industry chain structure, international market analysis etc. This report covers the global ...
Breaking Medicine News(10 mins):Health News:The Latest Treatment Options for Seven Common Skin Issues 2Health News:NJ Top Docs Presents, Dr. Eugene Batelli of Metropolitan Ankle & Foot Care Specialists 2Health News:NJ Top Docs Presents, Dr. Eugene Batelli of Metropolitan Ankle & Foot Care Specialists 3Health News:Maricopa Community Colleges Launch Program To Help Youth In Foster Care Finish College 2Health News:Maricopa Community Colleges Launch Program To Help Youth In Foster Care Finish College 3Health News:Cheap David Gilmour Tickets at Madison Square Garden (MSG), Air Canada Center, United Center and Hollywood Bowl: Additional Dates for David Gilmour Go On Sale Today 2Health News:Calcium Propionate Market Global Suppliers and Manufacture Analysis 2Health News:Calcium Propionate Market Global Suppliers and Manufacture Analysis 3
... cold virus to deliver pluripotent cells circumvents safety concerns, ... Researchers report that they have sidestepped a major technical ... adult cells. , A team of Boston scientists developed ... -- which are functionally similar to embryonic stem cells, ...
... to Eat Right, Move More and ... Milk Their Diets, NASHVILLE, Tenn., ... of different fad diets -- which seem to go in,and out of fashion ... three Americans -- including 27 percent of,Nashville residents -- remain overweight or obese., ...
... You Pink" campaign warns of "pinkwashing"., SAN ... respected watchdog of the breast cancer movement - ... Pink" campaign. The annual consumer,education campaign offers tips ... ( http://www.thinkbeforeyoupink.org ), This year,s campaign warns ...
... PHILADELPHIA, Sept. 25 The Council on Compulsive,Gambling of ... Systems Inc., and the Western Psychiatric Institute and,Clinic, our ... East Holiday Inn at 4751 Linden Road will host ... The Conference will be opened by,Tom Wolf, Secretary of ...
... 25 Sept. 26, 2008, marks the,100th anniversary ... 1908,Jersey City, N.J., was the first city in ... water. Since then, incidences of,waterborne diseases have plummeted, ... Director Gary Zimmerman,offers the following comments on behalf ...
... Employees Proves Worksite Wellness Programs Work, DALLAS, Sept. ... been recognized by the American Heart Association,s,Start! Fit-Friendly Companies ... place -- a 20 percent increase over last year., ... to get,Americans walking. Most adult Americans spend a majority ...
Cached Medicine News:Health News:Researchers Report Stem Cell Advance 2Health News:Researchers Report Stem Cell Advance 3Health News:Researchers Report Stem Cell Advance 4Health News:Message to Tennessee Residents: Forgo Fad Dieting and Join the Campaign for Healthy Weight 2Health News:Message to Tennessee Residents: Forgo Fad Dieting and Join the Campaign for Healthy Weight 3Health News:Breast Cancer Action Targets Yoplait in 'Think Before You Pink' Campaign; Calls for Yogurt Without Artificial Hormones 2Health News:Statewide Gambling Conference -- Series of 'Firsts' -- Begins 9-30-08 2Health News:AWWA Marks 100th Anniversary of Chlorine Disinfection 2Health News:American Heart Association Announces Start! Fit-Friendly Companies 2Health News:American Heart Association Announces Start! Fit-Friendly Companies 3
The Natural-Hip combines the surgical simplicity of a straight stem with many of the best features of an anatomic stem....
The Natural-Hip combines the surgical simplicity of a straight stem with many of the best features of an anatomic stem....
The Perfecta IMC Stems, manufactured from forged cobalt- chrome, are specifically designed for cemented femoral stem arthroplasty....
Simple straight stem design for the low-demand patient....
Medicine Products: